Kuala Lumpur, 20 November 2024 – Premier Integrated Labs, part of IHH Healthcare Malaysia, has become the inaugural provider to offer the Prosigna® Breast Cancer Test in Malaysia, marking a significant milestone in breast cancer care.

The test, crucial for assessing the risk of cancer recurrence, provides patients with quicker access to world-class diagnostics without the need to send samples abroad.

As the sole provider of the Prosigna test in Malaysia, Premier Integrated Labs sets a new standard in precision medicine and reaffirms its commitment to cutting-edge diagnostic services.

Mohd Hareeff Muhammed, Chief Executive Officer of Premier Integrated Labs, said, “By making the Prosigna Breast Cancer Assay available locally, we are ensuring that Malaysian patients can benefit from faster, more personalised insights that directly impact treatment decisions. This marks a significant leap in improving the healthcare journey for breast cancer patients across the country.”

The Prosigna Breast Cancer Test analyses specific gene activity in tumour tissue, providing a personalised risk assessment by examining factors such as tumour size, cell proliferation and lymph node involvement.

Using the nCounter Dx Analysis System, Premier Integrated Labs processes the test locally, eliminating the need for overseas lab submissions and ensuring quicker results.

This accelerated process gives doctors a clearer understanding of the cancer’s aggressiveness and recurrence risk (within 10 years), allowing for more informed treatment choices.

Premier Integrated Labs, known for its innovations in healthcare diagnostics, recently earned the prestigious UNIVANTS of Healthcare Excellence Award 2024, becoming the first and only winner from Asia. This achievement underscores the lab’s ongoing commitment to excellence and transformative solutions in healthcare.